Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1090-1098

  Fang, Yujiang ^a   Demarco, Vincent G ^a   Nicholl, Michael B ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 2; DEATH RECEPTOR 4; FAS ANTIGEN; HISTONE H2AX; PROTEIN KINASE B; PROTEIN P15; PROTEIN P21; PROTEIN P53; RESVERATROL;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MUTANT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY;

APOPTOSIS; CASPASE 3; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLIN D; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FAS LIGAND PROTEIN; HISTONES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861682542     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02272.x     Document Type: Article

References (51)

1. Siegel R, Ward E, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Leith JT. In vitro radiation sensitivity of the LNCaP prostate tumor cell line. Prostate 1994; 24: 119-24.
3. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
4. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: recent developments. Planta Med 2003; 69: 589-99.
5. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett 2003; 352: 203-6.
6. Ingham JL. 3, 5, 4′-Trihydroxystilbene as a phytoalexin from groundnuts (Arachis hypogea). Phytochem 1976; 15: 1791-3.
7. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of stylbene compounds of the roots of Ploygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull 1982; 30: 1766-70.
8. Uenobe F, Nakamur S, Miyazawa M. Antimutagenic effect of Resveratrol against Trp-P-1. Mutat Res 1997; 373: 197-200.
9. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997; 30: 91-113.
10. Shishodia S, Aggarwal BB. Resveratrol: a polyphenol for all seasons. Boca Raton, FL: CRC Press Taylor and Francis; 2006; 1-15.
11. Bhardwaj A, Sethi G, Vadhan-Raj S et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-302.
12. Scarlati F, Sala G, Ricci C et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007; 253: 124-30.
13. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702-11.
14. Fulda S, Debatin KM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 2005; 41: 786-98.
15. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 2005; 7: 1630-47.
16. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010; 5: e15627.
17. Su JL, Lin MT, Hong CC et al. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis 2005; 26: 1-10.
18. Diaz R, Nguewa PA, Diaz-Gonzalez JA et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009; 100: 932-40.
19. Zhao L, Wientjes MG, Au JLS. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994-8004.
20. Fang Y, Wei Y, DeMarco V, Chen K, Sharp GC, Braley-Mullen H. Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis. Am J Pathol 2007; 171: 875-87.
21. Fang Y, Sharp GC, Yagita H, Braley-Mullen H. A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J Pathol 2008; 216: 505-13.
22. Berridge MV, Tan AS, McCoy KD, Wang R. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 1996; 4: 12-20.
23. Fang Y, Yu S, Braley-Mullen H. TGF-β promotes proliferation of thyroid epithelial cells in IFN-γ-/- mice by downregulation of p21 and p27 via AKT pathway. Am J Pathol 2012; 180: 650-60.
24. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999; 39: 295-312.
25. Sherr CJ. G1 phaseprogression: cycling on cue. Cell 1994; 79: 551-5.
26. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15: 2612-24.
27. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995; 20: 187-90.
28. Thompson, CB Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
29. Zhang H, Xu Q, Krajewski S et al. BAR: an apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc. Natl Acad Sci USA 2000; 97: 2597-602.
30. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson FA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
31. Fang Y, Braley-Mullen H. Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1β converting enzyme inhibitory protein are protected from Fas-mediated apoptosis. Endocrinology 2008; 149: 1121-9.
32. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nat Cell Biol 2004; 6: 358-65.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
34. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009; 417: 411-21.
35. Lawless C, Wang C, Jurk D, Merz A, Zglinicki T, Passos JF. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010; 45: 772-8.
36. Bonner WM, Redon CE, Dickey JS et al. γH2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
37. Camphausen K, Brady KJ, Burgan WE et al. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of γH2AX foci. Mol Cancer Ther 2004; 3: 409-16.
38. Li WX, Franklin WA. Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells. Radiat Res 1998; 150: 190-4.
39. Zellweger T, Chi K, Miyake H et al. Enhenced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 3276-84.
40. Nayak BK, Krishnegowda NK, Galindo CA, Meltz ML, Swanson GP. Synergistic effect between curcumin (difruloylmethane) and radiation on clonogenic cell death independent of p53 in prostate cancer cells. J Cancer Sci Ther 2010; 2: 171-81.
41. Bernard D, Martinez-Leal JF, Rizzo S et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005; 24: 5543-51.
42. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines Prostate 1993; 23: 123-34.
43. Kelavkar UP, Cohen C, Kamitani H, Eling TE, Badr KF. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 2000; 21: 1777-87.
44. Zhou B, Liu X, Mo X et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003; 63: 6583-94.
45. Kelavkar UP, Badr KF. Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. Proc Natl Acad Sci USA 1999; 96: 4378-83.
46. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007; 12: 4839-54.
47. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3, 4, 5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 2007; 304: 273-85.
48. Zunino SJ, Storms DH. Resveratrol alters proliferative responses and apoptosis in human activated B lymphocytes in vitro. J Nutr 2009; 139: 1603-8.
49. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192: 547-56.
50. Gao FH, Hu XH, Li W et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010; 10: 610.
51. Vang O, Ahmad N, Baile CA et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol PLoS ONE 2011; 6: e19881.